The Effects of Pantoprazole on Kidney Outcomes.

Lonnie PyneAndrew SmythAmber O Molnar Paul Moayyedi Eva MuehlhoferSalim YusufJohn William Eikelboom Jacqueline Bosch Michael Walsh

Published in: Journal of the American Society of Nephrology : JASN (2024)

In this post-hoc analysis of the COMPASS trial pantoprazole resulted in a statistically significant greater rate of eGFR decline as compared to placebo. The clinical importance of this is uncertain.

Keyphrases

phase iii
small cell lung cancer
epidermal growth factor receptor
clinical trial
study protocol
tyrosine kinase
phase ii
open label
type diabetes
placebo controlled
metabolic syndrome